Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 12/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 8/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4520723 | 0.81 | SCN9A (0.46) | DRD2HTR2ASCN9AKCNH2SCN5A | |
| SCHEMBL4504199 | 0.80 | PGR (0.45) | DRD2HTR2ADRD3SCN9AKCNH2 | |
| SCHEMBL31277869 | 0.78 | TP53 (0.53) | TP53DRD2HTR2ADRD3 | |
| SCHEMBL4513633 | 0.78 | TP53 (0.53) | TP53DRD2HTR2ADRD3 | |
| SCHEMBL21810914 | 0.78 | TP53 (0.53) | TP53DRD2HTR2ADRD3 | |
| SCHEMBL4519989 | 0.76 | DRD2 (0.35) | TP53DRD2HTR2ADRD3SCN9A | |
| SCHEMBL21810779 | 0.76 | MTNR1A (0.48) | TP53DRD2HTR2ADRD3 | |
| SCHEMBL21810781 | 0.76 | MTNR1A (0.48) | TP53DRD2HTR2ADRD3 | |
| SCHEMBL4517412 | 0.75 | DRD2 (0.44) | DRD2HTR2ADRD3SCN9AKCNH2 | |
| SCHEMBL4517409 | 0.75 | DRD2 (0.44) | DRD2HTR2ADRD3SCN9AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| CN-101228121-A | Novel 8-sulfonyl-3 aminosubstituted chroman or tetrahydronaphtalene derivatives modulating the 5HT6 receptor | ASTRAZENECA AB (SE) | 2008-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | HTR6, HTR1D, HTR1A | TP53 4228/4885DRD2 56/4885HTR2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.